By contrast, promising data have been reported in recent years with the use of SGLT2-i and another antihyperglycemic drug class, the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA), which demonstrated benefits in terms of NAFLD/NASH amelioration in patients with T2DM through weight loss, a decrease in insulin resistance, or inhibition of lipogenesis in liver cells [24,25]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.